BioXcel Therapeutics Initiated Patient Enrollment In SERENITY At-home Pivotal Phase 3 Trial Of BXCL501 In At-home Setting For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia. The Trial Duration Currently Is Expected To Be 9 To 12 Months
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics has started patient enrollment for its SERENITY Phase 3 trial of BXCL501, targeting agitation in bipolar disorder and schizophrenia patients in an at-home setting. The trial is expected to last 9 to 12 months.
September 05, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioXcel Therapeutics has initiated a pivotal Phase 3 trial for BXCL501, which could significantly impact its market position if successful. The trial focuses on at-home treatment for agitation in bipolar disorder and schizophrenia.
The initiation of a Phase 3 trial is a critical step in drug development, indicating progress towards potential market approval. If successful, BXCL501 could enhance BioXcel's product portfolio and market position, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100